Physician profile
Scott Wofford
NPI 1437199049
$5,983.81
in general payments reported to CMS, 2019-2025
32 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $288 · 2021: $880 · 2022: $939 · 2023: $729 · 2024: $757 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,743 · Travel and Lodging: $298 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,743.45 |
| Travel and Lodging | $297.80 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,163.21 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Medtronic, INC. | $858.85 | 2024-2025 | Interstim |
| Braintree Laboratories, INC. | $619.38 | 2019-2023 | Suflave |
| Janssen Biotech, INC. | $425.28 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $290.25 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $218.41 | 2019-2022 | |
| Gilead Sciences, INC. | $217.96 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.05 | 2019-2025 | Entyvio |
| Boston Scientific Corporation | $122.95 | 2024 | Biliary Stent Introducer |
| Lilly USA, LLC | $110.74 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $107.43 | 2024-2025 | Zenpep |
| Celgene Corporation | $94.61 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $85.78 | 2019-2023 | Ocaliva |
| Madrigal Pharmaceuticals | $56.72 | 2024-2025 | Resmetirom, Rezdiffra |
| Genzyme Corporation | $48.73 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $38.25 | 2022 | |
| Phathom Pharmaceuticals, INC. | $38.12 | 2025 | Voquezna |
| Abiomed | $36.24 | 2023 | Impella |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.46 | 2019-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $34.07 | 2022-2023 | Dificid |
| Celltrion USA INC. | $29.40 | 2025 | Vegzelma |
| Organon LLC | $26.34 | 2024 | |
| Evoke Pharma, INC. | $26.32 | 2024 | |
| Biosense Webster, INC. | $24.59 | 2025 | Carto 3 |
| Alfasigma USA, INC. | $19.90 | 2021 | |
| Ardelyx, INC. | $18.97 | 2025 | Ibsrela |
| Redhill Biopharma INC. | $14.65 | 2020 | |
| Allergan, INC. | $13.88 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.60 | 2024 | |
| Qol Medical, LLC | $11.67 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Wofford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.